Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bemarituzumab + mFOLFOX6 in advanced gastric cancer
NCT03694522Phase 2Completed
- Sponsor
- Five Prime Therapeutics, Inc.
- Start
- Sep 2018
- Primary completion
- Sep 2020
- Modality
- Monoclonal Antibodies
- Countries
- 18
01
Overview
A Phase 2 trial of bemarituzumab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Five Prime Therapeutics, Inc.. Started Sep 2018; status: completed.
02
Drugs
bemarituzumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT03694522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03694522.